Aeterna Zentaris Inc
TSX:AEZS
Operating Margin
Aeterna Zentaris Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Aeterna Zentaris Inc
TSX:AEZS
|
18.9m CAD |
-839%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
327.6B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.7B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
134.5B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.6B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.7B USD |
-5%
|
Aeterna Zentaris Inc
Glance View
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company is headquartered in Montreal, Quebec and currently employs 17 full-time employees. The firm's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The firm focuses on the commercialization of macimorelin in Asia and the rest of the world.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Aeterna Zentaris Inc's most recent financial statements, the company has Operating Margin of -838.6%.
You don't have any saved screeners yet